Narcolepsy is a chronic sleep disorder that carries a high degree of disability and comorbidity. Patients often wait years for a proper diagnosis and treatment initiation, resulting in a tremendous negative impact to their quality of life. Pharmacotherapy for narcolepsy has historically been limited to traditional stimulants and twice-nightly GABA-B receptor agonist sodium oxybate. But recently, novel agents have been FDA approved, including solriamfetol, pitolisant, and once-nightly extended-release sodium oxybate, offering additional mechanisms and dosing regimens to positively impact patient care. During this podcast, sleep experts will discuss the latest clinical trials on the safety and efficacy of currently available novel therapies for EDS and cataplexy in patients with narcolepsy as well as strategies to improve treatment adherence.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/exploring-innovative-treatments-appraising-novel-pharmacotherapies-for-narcolepsy/
- Start Date: 2024-02-26 06:00:00
- End Date: 2024-02-26 06:00:00
- Credit Details: IPCE Credits: 0.75 hours
AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Avadel CNS Pharmaceuticals, LLC - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Sleep Medicine